Patents by Inventor Sylvie Chamoin

Sylvie Chamoin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11160797
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sylvie Chamoin, Pier Luca D'Alessandro, Mika Lindvall, Dimitrios Lizos, Nikolaus Johannes Stiefl, Sylvie Teixeira-Fouchard, Thomas Ullrich, Sven Weiler
  • Publication number: 20200360357
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: November 24, 2017
    Publication date: November 19, 2020
    Inventors: Luca Arista, Sylvie Chamoin, Pier Luca D'Alessandro, Mika Lindvall, Dimitrios Lizos, Nikolaus Johannes Stiefl, Sylvie Teixeira-Fouchard, Thomas Ullrich, Sven Weiler
  • Publication number: 20170326250
    Abstract: Disclosed herein are immunoconjugates comprising an inhibitor of Eg5 linked to an antigen binding moiety such as an antibody, that are useful for treating cell proliferative disorders. Also disclosed are novel inhibitors of Eg5 that can be used either alone or as part of an immunoconjugate to treat cell proliferation disorders. The Eg5 inhibitors include compounds of this formula as described herein: The invention further provides pharmaceutical compositions comprising these compounds and immunoconjugates, and compositions comprising the immunoconjugates or compounds with a therapeutic co-agent, and methods to use these compounds, conjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: October 7, 2016
    Publication date: November 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Paul Andrew BARSANTI, Sylvie CHAMOIN, Lionel DOUMAMPOUON-METOUL, Robert Martin GROTZFELD, Stephanie GUERRO-LAGASSE, Alexi KARPOV, Marc LAFRANCE, Cristina Montserrat NIETO-OBERHUBER, Grazia PIIZZI
  • Patent number: 9763952
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 19, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9751876
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 5, 2017
    Assignee: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Patent number: 9539260
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 10, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9498540
    Abstract: Disclosed herein are immunoconjugates comprising an inhibitor of Eg5 linked to an antigen binding moiety such as an antibody, that are useful for treating cell proliferative disorders. Also disclosed are novel inhibitors of Eg5 that can be used either alone or as part of an immunoconjugate to treat cell proliferation disorders. The Eg5 inhibitors include compounds of this formula as described herein: The invention further provides pharmaceutical compositions comprising these compounds and immunoconjugates, and compositions comprising the immunoconjugates or compounds with a therapeutic co-agent, and methods to use these compounds, conjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 22, 2016
    Assignee: NOVARTIS AG
    Inventors: Paul A. Barsanti, Sylvie Chamoin, Lionel Doumampouom-Metoul, Stephanie Guerro-Lagasse, Robert Martin Grotzfeld, Alexei Karpov, Marc Lafrance, Cristina Montserrat Nieto-Oberhuber, Grazia Piizzi
  • Publication number: 20160106753
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Applicant: Novartis AG
    Inventors: Giorgio CARAVATTI, Sylvie CHAMOIN, Pascal FURET, Klemens HOGENAUER, Konstanze HURTH, Christoph KALIS, Karen KAMMERTOENS, Ian LEWIS, Henrik MOEBITZ, Alexander Baxter SMITH, Nicolas SOLDERMANN, Romain WOLF, Frederic ZECRI
  • Patent number: 9073921
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 7, 2015
    Assignee: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Sarah Lewis, Jon Christopher Loren, Lin Lv, Valentina Molten, Alex Michael Saunders, Duncan Shaw, Roy Maxwell Turner, Vince Yeh
  • Publication number: 20150025059
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Applicant: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingswood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Patent number: 8883819
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 11, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentia Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Publication number: 20140322247
    Abstract: Disclosed herein are immunoconjugates comprising an inhibitor of Eg5 linked to an antigen binding moiety such as an antibody, that are useful for treating cell proliferative disorders. Also disclosed are novel inhibitors of Eg5 that can be used either alone or as part of an immunoconjugate to treat cell proliferation disorders. The Eg5 inhibitors include compounds of this formula as described herein: The invention further provides pharmaceutical compositions comprising these compounds and immunoconjugates, and compositions comprising the immunoconjugates or compounds with a therapeutic co-agent, and methods to use these compounds, conjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Applicant: NOVARTIS AG
    Inventors: Paul A. Barsanti, Sylvie Chamoin, Lionel Doumampouom-Metoul, Stephanie Guerro-Lagasse, Robert Martin Grotzfeld, Alexei Karpov, Marc Lafrance, Cristina Montserrat Nieto-Oberhuber, Grazia Piizzi
  • Publication number: 20140275175
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: NOVARTIS AG
    Inventors: Christopher Michael Adams, Sylvie Chamoin, Qi-Ying Hu, Chun Zhang
  • Publication number: 20140249177
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: February 21, 2014
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Ian BRUCE, Sylvie CHAMOIN, Stephen Paul COLLINGWOOD, Pascal FURET, Vikki FURMINGER, Sarah LEWIS, Jon Christopher LOREN, Lin LV, Valentina MOLTEN, Alex Michael SAUNDERS, Duncan SHAW, Roy Maxwell TURNER, Vince YEH
  • Patent number: 8809545
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 19, 2014
    Assignee: Novartis AG
    Inventors: Sylvie Chamoin, Qi-Ying Hu, Julien Papillon
  • Patent number: 8778972
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: July 15, 2014
    Assignee: Novartis AG
    Inventors: Qi-Ying Hu, Sylvie Chamoin, Christopher M. Adams, Chun Zhang
  • Publication number: 20130296309
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 7, 2013
    Inventors: Sylvie Chamoin, Qi-Ying Hu, Julien Papillon
  • Patent number: 8575160
    Abstract: The present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, R7 and p are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: November 5, 2013
    Assignee: Novartis AG
    Inventors: Robert Sun, Lauren G. Monovich, Sylvie Chamoin, John Westbrook
  • Publication number: 20130237519
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: August 30, 2012
    Publication date: September 12, 2013
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Patent number: 8519142
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 27, 2013
    Assignee: Novartis AG
    Inventors: Sylvie Chamoin, Qi-Ying Hu, Julien Papillon